Pfizer (NYSE:PFE) Shares Unloaded Sen. John Boozman

Senator John Boozman (R-Arkansas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 06th, the Senator disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on February 13th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Sprott Lithium Miners ETF (NASDAQ:LITP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Invesco Short Term Treasury ETF (NYSEARCA:TBLL) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Motorola Solutions (NYSE:MSI) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Ecolab (NYSE:ECL) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 2/26/2025.

Pfizer Price Performance

Pfizer stock opened at $26.71 on Friday. The firm has a market capitalization of $151.35 billion, a price-to-earnings ratio of 18.94, a PEG ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a fifty day simple moving average of $26.30 and a 200-day simple moving average of $27.25.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.44%. The ex-dividend date was Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PFE shares. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. Finally, Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Hedge Funds Weigh In On Pfizer

Several large investors have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.